SOSUA BAY, Dominican Republic, Sept. 21, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI) CEO, Armando Casciati, announced today that Dr. Keunmyoung David Lee, Ph.D. will complete his training at RNL Bio Ltd. in Seoul South Korea this week. As part of the license agreement with RNL Bio that RegenoBody has, RNL Bio is obligated to provide training for designated personnel. Dr. Lee, who not only has an extensive background in stem cell research, but who also speaks fluent Korean, has spent the last week and will spend part of this week in training and educational instruction on the methodologies and techniques employed by RNL Bio in their laboratory as well as the systems and procedures they use in the cataloging and management of the stem cell cultures. Mr. Casciati went on to say that "with the completion of the training, coupled with the installation of the processing laboratory, our planned opening for business is making great progress. We are very gratified that we are now so close to meeting our planned objective of delivering world class services to needy patients."
Dr. Keunmyoung David Lee, Ph.D. is a widely published and respected research scientist with expertise in the areas of biochemistry, molecular biology and cell biology with a particular focus on Mesenchymal Stem Cell research. He has over 25 years of biotechnology lab experience, including 10 years experience in managing biotechnology company operations. Dr. Lee was critical in the initial laboratory setup and ongoing management of the company where he has worked over the past 8 years. Prior to that, Dr. Lee assisted in launching Rexahn Corporation and served as Director of Discovery Program, initiating and managing R&D in various areas including anti-cancer, anti-viral, bioinformatics and computational biology. Given these positions, along with previous roles he has served—as Senior Scientist at Osiris Therapeutics and as a Post Doctoral Fellow at Case Western Reserve University—Dr. Lee is recognized as one of the leading experts in the most cutting-edge areas of gene therapy, tissue generation and cancer research, specifically with respect to the use of Mesenchymal Stem Cells.
Dr. Lee received his Ph.D. in Genetics at University of California, Riverside, M.S. in Biochemistry at Emory University and B.S. in Chemistry and Education in Seoul National University. He is a member of various professional science and research associations, including NIH CounterACT Network Research Symposium, American Society of Gene Therapy and The Society of Biomedical Research. Dr. Lee has been widely published in peer-reviewed journals and publications, and has delivered numerous scientific orations and seminars, on topics within the scope of gene therapy and cancer research, most notably on his research and publications on Mesenchymal Stem Cells.
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A: RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective adult stem cells in the world today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.
This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the company undertakes no obligation to update such statements.
CONTACT: Proton Laboratories, Inc. Investor Relations Tyler Cornell Emergingmarkets3@yahoo.com